Kairos Pharma, Ltd. · AMEX:KAPA
Kairos Pharma — Corporate Update (September 2025)
7 slides from Kairos Pharma's corporate update, Sep 18, 2025
Slide 1: ENV105 (Carotuximab) in Prostate Cancer
ENV105 (Carotuximab KAIROS IN POSTE CANCER Androgen Ke sae, Receptor signaling Inhibitor A. - The inhibition of androgen signaling \ carotuximab anny promotes the CD105 expression N we TGFR _ os BMP4 ¥ - (€D105 signaling promotes survival and eC lineage plasticity (stem-like features) ENV105 (carotu
Slide 2: Randomized Phase 2 Trial: Apalutamide with or without ENV105
ENV105 K KAIROS | IN PROSTATE CANCER PRESENT RANDOMIZED PHASE 2 TRIAL: NCT03418324 Apalutamide with or without ENV105 lupron extend treatment with Ouse combination therapy @@ apalutamide single agent enzalutamide @,.... . forcompassionate use sain @-© apalutamide + ENV105 abiraterone @su«= Prostate
Slide 3: Patient Summary Phase 2 trial: Apalutamide and ENV105 in mCRPC
Patient Summary Phase 2 triat NCTO5534646 Apalutamide and ENV105 for the Treatment of Metastatic Castration-Resistant Prostate Cancer KAIROS K PHARMA Engg THERAPEUTICS AKAIROS PHARMA company Sponsored by: 001 002 003 004 005 006 007 008 009 010 68 76 73 82 60 68 79 71 69 85 Abiraterone Enzalutamide,
Slide 4: Patient Summary Phase 2 trial: Adverse Events
Patient Summary Phase 2triat NCT05534646 Apalutamide and ENV105 for the Treatment of Metastatic Castration-Resistant Prostate Cancer event | tgrades | Grades Epistaxis Headache Gum bleeding Fatigue Nausea Pruritis Anemia Anorexia Dehydration Dizziness Edema Rash 8 MO NN NY Ww WO WO KR BR C1 © ooooo0
Slide 5: Radiographic PFS points of reference
Radiographic PFS points of reference K mae No. at Risk Cabazitaxel Androgen-si targeted inhibitor Percentage of Patients with Progression-free Survival $s CARD Trial ARPI-switch median PFS = 3.7 months Cabaxitaxel median PFS = 8 months N = 255 ARPI-switch median PFS = 5.6 months 177_u-PSMA median PF
Slide 6: Progression Free Survival
KK sae Progression Free Survival NCT05534646 Weeks Sponsored by: = th w b a o ~ © ERAPEUTICS o o o Oo o Oo o AKAIROS PHARMA company > Stillontriat @) Unrelated withdrawal Median PFS = 13 months* (expected 3.7 months) * Patients continue to be evaluated
Slide 7: Change in PSA
Change in PSA NCT05534646 40 ax 20 2 = 0 — em i. fo} & -40 8 -60 & -80 KAIROS K PHARMA JERAPEUTICS AKAIROS PHARMA company Sponsored by: Comparing baseline pre- treatment PSA to nadir PSA values